GNPs can be modified by ligands or tumor-specific recognition molecules to deliver targeted drugs such as transferrin, folic acid, epidermal growth factor (EGF), or any number of monoclonal antibodies can be conjugated to the surface of GNPs (Vines et al., 2019). Here, EGF is linked to neoplasm.